We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Paired comparison of methylene blue- and amotosalen-treated plasma and cryoprecipitate.
- Authors
Backholer, L.; Wiltshire, M.; Proffitt, S.; Cookson, P.; Cardigan, R.
- Abstract
Background and objectives Cryoprecipitate is used in the treatment of patients with acquired hypofibrinogenaemia. Studies have not directly compared cryoprecipitate produced following pathogen inactivation ( PI) of fresh-frozen plasma ( FFP) using different systems. The effects of methylene blue ( MB) and amotosalen ( AS) PI systems on the quality of FFP and cryoprecipitate were investigated in a paired study. Materials and Methods Seven group A and 7 group O pools of plasma were prepared and split into individual units and rapidly frozen to produce FFP. Units of FFP were thawed and either PI treated with MB or amotosalen, or left untreated (control). Samples of FFP along with the corresponding cryoprecipitate were tested for a range of coagulation factors, thrombin generation ( TGT) and rotational thromboelastometry ( ROTEM). Results AS- FFP showed a smaller decrease following treatment for most coagulation factors analysed than MB- FFP, except fibrinogen (antigen) and factor VII, partly due to lower volume losses. There was no significant difference between treatment methods for fibrinogen content of cryoprecipitate with treated units meeting current UK specification, or TGT and ROTEM parameters studied. Conclusions MB-cryo contained a significantly higher content of FVIII and lower content of FXIII when compared to AS-cryo, with no difference in fibrinogen activity.
- Subjects
BLOOD coagulation factors; METHYLENE blue; BLOOD plasma; FROZEN blood; FIBRINOGEN; THROMBIN
- Publication
Vox Sanguinis, 2016, Vol 110, Issue 4, p352
- ISSN
0042-9007
- Publication type
Article
- DOI
10.1111/vox.12368